161 research outputs found
Kinetics of Circulating Plasma Cell-Free DNA in Paediatric Classical Hodgkin Lymphoma
Levels of plasma cell-free DNA (cfDNA) of a large series of children with classical Hodgkin lymphoma (cHL) were evaluated and analyzed at diagnosis and during chemotherapy treatment in relation with clinical characteristics. CfDNA levels in cHL patients were significantly higher compared with controls (p=0.002). CfDNA at diagnosis was correlated with presence of B symptoms (p=0.027) and high erythrocyte sedimentation rate (p=0.049). We found that the increasing of plasma cfDNA after first chemotherapy cycle seems to be associated with a worse prognosis (p=0.049). Levels of plasma cfDNA might constitute an interesting non-invasive tool in cHL patients' management
Are all cases of paediatric essential thrombocythaemia really myeloproliferative neoplasms? Analysis of a large cohort
Sporadic essential thrombocythaemia (ET) is rare in paediatrics, and the
diagnostic and clinical approach to paediatric cases cannot be simply copied
from experience with adults. Here, we assessed 89 children with a clinical
diagnosis of ET and found that 23 patients (258%) had a clonal
disease. The JAK2 V617F mutation was identified in 14 children, 1 child
had the MPL W515L mutation, and 6 had CALR mutations. The monoclonal
X-chromosome inactivation pattern was seen in six patients (two with
JAK2 V617F and two with CALR mutations). The other 66 patients
(742%) had persistent thrombocytosis with no clonality. There were no
clinical or haematological differences between the clonal and non-clonal
patients. The relative proportion of ET-specific mutations in the clonal
children was much the same as in adults. The higher prevalence of nonclonal
cases suggests that some patients may not have myeloproliferative
neoplasms, with significant implications for their treatment
FDG PET in response evaluation of bulky masses in paediatric Hodgkin's lymphoma (HL) patients enrolled in the Italian AIEOP-LH2004 trial
Favorable outcome of SARS-CoV-2 infection in pediatric hematology oncology patients during the second and third pandemic waves in Italy: a multicenter analysis from the Infectious Diseases Working Group of the Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP)
COVID-19 has a mild clinical course with low mortality rate in general pediatric population, while variable outcomes have been described in children with cancer. Infectious diseases working party of the AIEOP collected data on the clinical characteristics and outcomes of SARS-CoV-2 infections in pediatric oncology/hematology patients from April 2020 to May 2021, including the second and the third waves of the pandemic in Italy. Factors potentially associated with moderate, severe, or critical COVID-19 were analyzed. Of the 153 SARS-Cov2 infections recorded, 100 were asymptomatic and 53 symptomatic. The course of COVID-19 was mild in 41, moderate in 2, severe in 5, and critical in 5 children. A total of 40.5% of patients were hospitalized, ten requiring oxygen support and 5 admitted to the intensive care unit. Antibiotics and steroids were the most used therapies. No patient died due to SARS-CoV-2 infection. Infections occurring early (< 60 days) after the diagnosis of the underlying disease or after SCT were associated to moderate, severe, and critical disease compared to infections occurring late (> 60 days) or during maintenance therapy. In the patients on active chemotherapy, 59% withdrew the treatment for a median of 15 days. SARS-CoV-2 presented a favorable outcome in children with cancer in Italy during the pandemic. Modification of therapy represents a major concern in this population. Our findings suggest considering regular chemotherapy continuation, particularly in patients on maintenance therapy or infected late after the diagnosis
Consensus on COVIDâ19 Vaccination in Pediatric Oncohematological Patients, on Behalf of Infectious Working Group of Italian Association of Pediatric Hematology Oncology
Vaccines represent the best tool to prevent the severity course and fatal consequences of the pandemic by the new Coronavirus 2019 infection (SARSâCoVâ2). Considering the limited data on vaccination of pediatric oncohematological patients, we developed a Consensus document to support the Italian pediatric hematological oncological (AIEOP) centers in a scientifically correct communication with families and patients and to promote vaccination. The topics of the Consensus were: SARSâCoVâ2 infection and disease (COVIDâ19) in the pediatric subjects; COVIDâ19 vaccines (type, schedule); who and when to vaccinate; contraindications and risk of serious adverse events; rare adverse events; third dose and vaccination after COVIDâ19; and other general prevention measures. Using the Delphi methodology for Consensus, 21 statements and their corresponding rationale were elaborated and discussed with the representatives of 31 centers, followed by voting. A high grade of Consensus was obtained on topics such as the potential risk of severe COVIDâ19 outcome in pediatric oncohematological patients, the need for vaccination as a preventative measure, the type, schedule and booster dose of vaccine, the eligibility of the patients for vaccination, and the timing, definition, and management of contraindications and serious adverse events, and other general prevention measures. All 21 of the statements were approved. This consensus document highlights that children and adolescents affected by hematological and oncological diseases are a fragile category. Vaccination plays an important role to prevent COVIDâ 19, to permit the regular administration of chemotherapy or other treatments, to perform control visits and hospital admissions, and to prevent treatment delays
Late mortality and causes of death among 5-year survivors of childhood cancer diagnosed in the period 1960â1999 and registered in the Italian Off-Therapy Registry
Specie esotiche invasive di rilevanza unionale in Italia: aggiornamenti e integrazioni
La Commissione Europea (CE) ha inserito ad oggi 36 taxa esotici vegetali nella lista delle specie esotiche invasive di rilevanza unionale ai sensi del Regolamento (UE) n. 1143/2014 del Parlamento Europeo e del Consiglio, recante disposizioni volte a prevenire e gestire lâintroduzione e la diffusione delle specie esotiche invasive. La lista delle specie di rilevanza unionale viene periodicamente aggiornata e include quelle specie che rappresentano una grave minaccia per la biodiversitĂ , ma anche per la salute dei cittadini e le attivitĂ economiche nei territori dellâUnione Europea e che necessitano di una gestione concertata a livello comunitario. La CE vigila sullo stato di ogni taxon grazie anche a periodiche rendicontazioni da parte dei paesi dell'Unione. In vista di tali report, tra il 2020 e il 2021 Ăš stata definita e integrata la distribuzione di queste specie in Italia
ChemInform Abstract: NONSTEROIDAL ANTIINFLAMMATORY DRUGS. STEREOISOMERS OF HOMOLOGS OF 2-(4-BIPHENYLYL)-3-HYDROXYPROPIONIC ACIDS. PART XII
- âŠ